赵, 丰 – page 6 – eisai china lnc.-pg电子app

 赵, 丰 – page 6 – eisai china lnc.-pg电子app

entries by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its u.s. subsidiary eisai inc. has entered into a memorandum of understanding with c2n diagnostics (“c2n”) that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including alzheimer’s disease (ad), may help patients receive a timely diagnosis and appropriate treatment. collaborating with c2n, eisai inc. will work to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment in clinical practice outside of clinical trial settings in the u.s. blood-based assays could result in the development of new standards in clinical care that may enable timely and accurate diagnoses for people living with cognitive impairment.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and lifenet insurance company (headquarters: tokyo, president: ryosuke mori, “lifenet”) announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in japan’s aging society.

eisai co. ltd (headquarters: toyoko, ceo: haruo naito, “eisai”) announced today that the company will present research from its alzheimer’s disease (ad) pipeline, including new data for lecanemab (ban2401), an investigational anti-amyloid beta (aβ) protofibril antibody for the treatment of mild cognitive impairment (mci) due to alzheimer’s disease (ad) and mild ad (collectively known as early ad) with confirmed presence of amyloid pathology in the brain, at the alzheimer’s association international conference (aaic) to be held in san diego, ca and virtually from july 31 to august 4, 2022. eisai will present data and research in three oral and 18 poster presentations at the meeting.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that eisai has acquired a majority of the shares issued by arteryex inc. (headquarters: tokyo, ceo: li dongying, “arteryex”), a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of […]

eisai to present abstracts on lenvatinib at 2022 asco gastrointestinal cancers symposium

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: lenvima®, the orally available kinase inhibitor, “lenvatinib”) will be given at the 2022 american society of clinical oncology (asco) gastrointestinal cancers symposium (#gi22), taking place in-person in san francisco, california, and virtually, from january 20 to 22, 2022.

eisai enters into exclusive licensing agreement with roivant concerning investigational anticancer agent h3b-8800,a splicing modulator

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a license agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent h3b-8800 to a subsidiary of roivant sciences ltd. (nasdaq: roiv, headquarters: london, u.k., “roivant”). h3b-8800 (roivant’s development code: rvt-2001) is a splicing modulator compound, discovered by eisai’s u.s. research subsidiary h3 biomedicine inc., which is undergoing development as an investigational anticancer agent.